Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Finding MSL Success in Cross Therapeutic Transitions
Summary
In this episode, Tom Caravela welcomes Mitch D'Rosario and Deanna Tucker to discuss the intricacies of switching therapeutic areas as a Medical Science Liaison (MSL). They share personal experiences and address common concerns when transitioning into new therapeutic spaces. The conversation delves into strategies for gaining expertise, accessing Key Opinion Leaders (KOLs), and overcoming challenges unique to different therapeutic areas. The guests emphasize the importance of leveraging transferable skills and relationship equity to establish credibility. They also touch on the impact of AI on MSL job applications and offer insights on adding value to KOLs. The episode concludes with reflections on building strong professional relationships.
Key Points
- Transitioning between therapeutic areas can be daunting, but leveraging core MSL skills, such as pre-call planning and building relationships, is crucial for success.
- Humility and a willingness to learn are essential when switching therapeutic areas, as they help build credibility with new KOLs and adapt to new scientific landscapes.
- Leveraging your network and showcasing your transferable skills and experience can significantly aid in making a successful therapeutic area transition.
medical science liaison, therapeutic area transition, key opinion leaders, leveraging transferable skills, building professional relationships
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary